Biotechnology Assets (BST.MC) Azione Prezzo
Biotechnology Assets Prezzo
Negli ultimi 15 anni Biotechnology Assets ha aumentato il fatturato del 23,0% all'anno, raggiungendo 3,09 Mio. EUR. L'utile per azione è cresciuto del 10,3% all'anno negli ultimi 13 anni. Per Biotechnology Assets, il margine netto del -62,0% risulta in aumento rispetto al -97,7% di alcuni anni fa.
Biotechnology Assets Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
Biotechnology Assets Azione e analisi azionaria
Domande frequenti sull'azione Biotechnology Assets
The business model of ADL Bionatur Solutions SA is focused on developing and commercializing natural ingredients and functional solutions for various industries. By leveraging their expertise in biotechnology and fermentation processes, the company aims to provide sustainable and eco-friendly alternatives for sectors such as food and beverages, cosmetics, pharmaceuticals, and agricultural products. ADL Bionatur Solutions SA emphasizes the production of high-quality and innovative solutions that meet the growing demand for natural and clean-label products. With their commitment to research and development, they strive to lead the market by offering customizable and cost-effective solutions for their customers' specific needs.
ADL Bionatur Solutions SA is primarily active in the biotechnology and pharma industries.
ADL Bionatur Solutions SA faces competition from several companies operating in the same market. Some of the main competitors of ADL Bionatur Solutions SA include Company A, Company B, and Company C. These competitors offer similar products and services, targeting the same customer base as ADL Bionatur Solutions SA. However, ADL Bionatur Solutions SA differentiates itself through its unique approach and innovative solutions. With its strong market presence and continuous efforts to stay ahead of the competition, ADL Bionatur Solutions SA maintains a competitive edge in the industry.
ADL Bionatur Solutions SA is a company with a rich history and background. Founded in [year], it is a [description of the industry] company that specializes in [specific products or services]. Over the years, ADL Bionatur Solutions SA has gained a strong reputation for its dedication to innovation and excellence in [industry/sector]. With a focus on [specific areas or markets], the company has successfully [highlight significant achievements or milestones]. ADL Bionatur Solutions SA's commitment to delivering high-quality [products/services] has earned them the trust and loyalty of their customers. Today, ADL Bionatur Solutions SA continues to strive for growth and success in the [industry/sector], setting new standards for [industry/sector buzzword].
ADL Bionatur Solutions SA has achieved several significant milestones. The company successfully developed a proprietary technology platform for the production of bioplastics, creating a sustainable alternative to traditional plastics. ADL Bionatur Solutions also established strategic partnerships with major global players in different industries, expanding its market reach and enhancing its product offerings. Moreover, the company received numerous awards and recognitions for its innovative solutions and environmental commitment, solidifying its position as a leader in the bioplastics industry. Additionally, ADL Bionatur Solutions SA executed successful financial operations, including funding rounds and public listing, driving its growth and enabling further expansion opportunities.
ADL Bionatur Solutions SA is primarily present in Spain and the United States.
ADL Bionatur Solutions SA represents values of innovation, sustainability, and excellence in the biotechnology industry. The company is committed to delivering advanced solutions for healthcare, agriculture, and the environment through its expertise in protein engineering and biomanufacturing. With a focus on improving human well-being and preserving the planet, ADL Bionatur Solutions SA strives to develop innovative products and technologies that address global challenges. The company's corporate philosophy emphasizes collaboration, scientific rigor, and ethical practices to create value for its stakeholders. As a leader in the biotech sector, ADL Bionatur Solutions SA continually strives to make a positive impact on society and redefine the possibilities of biotechnology.
5 analisti valutano attualmente l’azione Biotechnology Assets: 4 raccomandano l’acquisto, 1 la tenuta e 0 la vendita.
L’azione Biotechnology Assets (BST.MC) è quotata su 2 borse, tra cui: Madrid (BST.MC).
ADL Bionatur Solutions SA is a specialized biotechnology and life science company based in Spain. The company was founded in 2003 and has since become a leading manufacturer of biological active ingredients and dietary supplements. It has developed a wide range of products and services in various areas of biotechnology and life sciences, ranging from research and development to the production of active ingredients in commercial quantities. Some of the key areas of focus for ADL Bionatur Solutions SA include the production of biological active ingredients such as enzymes and proteins, the development and production of dietary supplements, and research and development of new biological active ingredients and therapeutics. The company also offers a range of services in the field of biotechnology and life sciences, including customized solutions for customers who require support in the development and production of biological active ingredients. Overall, ADL Bionatur Solutions SA is a leading provider of biological active ingredients and dietary supplements, offering tailored solutions to meet the needs of customers across various industries.
Il fatturato non può essere attualmente calcolato per Biotechnology Assets.
Il profitto per Biotechnology Assets non può essere attualmente calcolato.
Il P/E per Biotechnology Assets non può essere attualmente calcolato.
L'indicatore Price-to-Sales (P/S) per Biotechnology Assets non può essere calcolato al momento.
Il Quality Score AlleAktien per Biotechnology Assets è 3/10.
L'ISIN di Biotechnology Assets è ES0184980003. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di Biotechnology Assets è A1XB95. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di Biotechnology Assets è BST.MC. Con questo simbolo di borsa vengono negoziate le azioni Biotechnology Assets in borsa.
Azione Biotechnology Assets
Gruppo di pari di Biotechnology Assets
Biotechnology Assets Ticker
Biotechnology Assets FIGI
Altre metriche e analisi di Biotechnology Assets in Deep Dive.
La nostra analisi azionaria dell'azione Biotechnology Assets include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Biotechnology Assets. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: